The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally

Abstract

Background: Gastric Cancer (GC) is the fourth most deadly cancer worldwide. Enhanced understanding of its key epidemiological and molecular drivers is urgently needed to lower the incidence and improve outcomes. Furthermore, tumor biology in European (EU) and Latin American (LATAM) countries is understudied. The LEGACy study is a Horizon 2020 funded multi-institutional research approach to 1) detail the epidemiological features including risk factors of GC in current time and 2) develop cost-effective methods to identify and integrate biological biomarkers needed to guide diagnostic and therapeutic approaches with the aim of filling the knowledge gap on GC in these areas.

Methods: This observational study has three parts that are conducted in parallel during 2019-2023 across recruiting centers from four EU and four LATAM countries: Part 1) A case-control study (800 cases and 800 controls) using questionnaires on candidate risk factors for GC, which will be correlated with clinical, demographic and epidemiological parameters. Part 2) A case-control tissue sampling study (400 cases and 400 controls) using proteome, genome, microbiome and immune analyses to characterize advanced (stage III and IV) GC. Patients in this part of the study will be followed over time to observe clinical outcomes. The first half of samples will be used as training cohort to identify the most relevant risk factors and biomarkers, which will be selected to propose cost-effective diagnostic and predictive methods that will be validated with the second half of samples. Part 3) An educational study, as part of our prevention strategy (subjects recruited from the general public) to test and disseminate knowledge on GC risk factors and symptoms by a questionnaire and informative video. Patients could be recruited for more than one of the three LEGACy studies.

Discussion: The LEGACy study aims to generate novel, in-depth knowledge on the tumor biological characteristics through integrating epidemiological, multi-omics and clinical data from GC patients at an EU-LATAM partnership. During the study, cost-effective panels with potential use in clinical decision making will be developed and validated.

Trial registration: ClinicalTrials.gov Identifiers: Part 1: NCT03957031 . Part 2: NCT04015466 . Part 3: NCT04019808 .

Keywords: Gastric cancer; Prevention; Tumor microenvironment.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1

Overview LEGACy; Indicating which centers contribute to which determination and related parts of the project. ANAX: Anaxomics SL (Spain); ECPC: European Cancer Patient Coalition (Belgium); GENPAT: Genpat SL (Paraguay); IAF: Institute Alexandre Fleming (Argentine); INCAN: Caner Insitute of Mexico (Mexico); INCLIVA: Biomedical Research Center INCLIVA (Spain); PUC: Pontificia University of Chile (Chile); ULEI: University of Leipzig (Germany); VHIO: Valld’Hebrón Insitut of Oncology (Spain); VUMC: Amsterdam UMC (Netherlands). IHC: Immunohistochemistry; ISH: In situ hybridization. Map created with mapchart.net. Figure created with BioRender.com

Fig. 2

Subjects, inclusion criteria (IC) and exclusion criteria (EC) for three sub-studies of the LEGACy project. (YO: years old; ICS: Informed consent sheet; GC: gastric cancer; GEJ: gastro-esophageal junction cancer; w/o: without)